Chrysalis Biotherapeutics, Inc. — Form D
Chrysalis Biotherapeutics, Inc. of GALVESTON, TX, a company, filed a Form D exempt-offering notice with the SEC on 2024-03-22. The offering totals $3.0M, of which $515K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2024-03-22
- Form: D
- Accession: 0002016438-24-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $515K
- Remaining: $2.5M
- Minimum investment: $10K
- Investors: 12
- Date of first sale: 2023-11-28
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-508350
Issuer
- Name: Chrysalis Biotherapeutics, Inc.
- CIK: 0002016438
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 2200 MARKET ST, SUITE 606, GALVESTON, TX, 77550
- Phone: 409-497-4038
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Darrell Carney | Director | Galveston, TX |
| Marie Robb | Director | Galveston, TX |
| James Ryaby | Director | Galveston, TX |
| Timothy Schmidt | Director | Galveston, TX |
| Jeffery Sheldon | Director | Galveston, TX |
| Darrell Carney | Executive Officer | Galveston, TX |
| Lauri Sower | Executive Officer | Galveston, TX |
More